" Except for the few who might be following Anavex science, most of the conference audience may have never heard of the sigma-1 receptor; or understand in any way that its proper activation could somehow stop or reverse the progression of Alzheimer’s symptoms." And by 4:30 on Thursday most of the attendees will be long gone and won't give a schitt.
Why is it interesting that nothing was mentioned about Anavex? It's a big deal in the echo chamber because we all have a personal interest in the outcome, but I'd venture that most people attending CTAD are only familiar with Anavex at the most cursory levels.
There are so many other presenters, each believing his or her research is the most important on the entire slate. Anavex right now is still a small fish in a big pond. Maybe our fish becomes a little more visible on Thursday afternoon.
News 
Market Data 
Discover 
